Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLE-4: Buparlisib + Paclitaxel in HER2- Advanced Breast Cancer
NCT01572727Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing BKM120 + Paclitaxel with Placebo + Paclitaxel (2 arms). Primary endpoint: Progression-free Survival. Started Aug 2012; status: completed.
02
Drugs
buparlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01572727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572727.